WP
PCRX icon

Woodline Partners’s Pacira BioSciences PCRX Stock Holding History

Woodline Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-127,371
Closed -$4.3M – 608
2023
Q4 		$4.3M Buy
127,371
+18,964
+17% +$555K 0.05% 331
2023
Q3 		$3.33M Buy
108,407
+31
+0% +$1.12K 0.04% 353
2023
Q2 		$4.34M Buy
108,376
+5
+0% +$207 0.05% 311
2023
Q1 		$4.42M Buy
108,371
+17,724
+20% +$705K 0.06% 312
2022
Q4 		$3.5M Sell
90,647
-464
-0.5% -$22.6K 0.05% 379
2022
Q3 		$4.85M Buy
91,111
+3,279
+4% +$182K 0.07% 299
2022
Q2 		$5.12M Buy
87,832
+32
+0% +$2.1K 0.08% 258
2022
Q1 		$6.7M Hold
87,800
– – 0.11% 217
2021
Q4 		$5.28M Buy
+87,800
New +$4.84M 0.08% 276
2020
Q3 		– Sell
-200,720
Closed -$10.5M – 209
2020
Q2 		$10.5M Buy
200,720
+8,488
+4% +$355K 0.42% 71
2020
Q1 		$6.45M Sell
192,232
-199,236
-51% -$8.28M 0.46% 69
2019
Q4 		$17.7M Buy
+391,468
New +$16.6M 0.72% 49

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Woodline Partners's PCRX Position: Q1 2024 in Review

Woodline Partners sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 127,371 shares — an estimated $4.3M sold.

Woodline Partners first reported a position in PCRX in Q4 2019 and held it in 12 quarters. The position peaked at $17.7M in Q4 2019. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

  • Woodline Partners reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
  • Woodline Partners sold 127,371 Pacira BioSciences shares in Q1 2024, an estimated $4.3M.
  • Woodline Partners first reported a position in Pacira BioSciences in Q4 2019 and held it in 12 quarters.
  • Woodline Partners's Pacira BioSciences position peaked at $17.7M in Q4 2019.
  • 270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.